1 1 7LMS0271 TMS Online Seminar Assignment (2021-2022): 25% Set by Lisa Lione in week 12. Submission of TMS seminar powerpoint presentation Deadline: Week 16 (Sunday 14th November 2021, 8pm) o Submit on studynet as a powerpoint document with notes (pptx, under Assignment page) o The powerpoint template provides a guide to Slide number. o Your online seminar presentation will be scheduled in week 17 (Tuesday 17th November 2020) Presentation delivery time of 15 minutes plus 5 minutes of questions to follow. The Grading criteria mark scheme Oral presentation criteria and assessment (Masters) (L7) will be adopted. o Content (70% of marks) : ? structured and planning, required background information, critical analysis, context (e.g. competitor), drew correct and relevant conclusions, correctly referenced and relevant sourced literature o Delivery (30% of marks): ? speaker communicated clearly and could deal adequately with questions, good audience interaction, well designed and implemented visual aids Graduate attributes: PEE, L&RS, IDBA PTS: A, IM, COMW, PS, SERP Learning Outcomes: KU1 and SA1, SA2, SA3 Online Seminar Assignment Drug discovery is expensive so choosing the right target based upon target validation, feasibility of screening and competitor landscape is vital to avoid wasting large amounts of money. Novel drug candidates acting on therapeutic targets often fail in clinical trials through lack of efficacy. You have each been provided with one target as a potential therapeutic target for a human disease (Please refer to Table 1). This assignment asks you to use your knowledge from lectures on pharmacology, toxicology, target Identification and Validation and preclinical in vitro/in vivo screening to independently research your assigned novel target and prepare a presentation following the content guidance provided on the powerpoint slide outline template. Recommended reading and resources (also see reading list on Canvas) ? Excellent guide on pharmacological targets http://www.guidetopharmacology.org/index.jsp ? OMIM is a comprehensive compendium of human genes and genetic phenotypes https://www.ncbi.nlm.nih.gov/omim?db=OMIM&itool=toolbar 2 2 ? Drug discovery and development. Raymond Hill and Humphrey Rang 3 rd edition (2021). (E-book) Useful chapter for considering in vitro and in vivo screens for your chosen target ? Principles of Drug discovery and development. Benjamin Blass, 2 nd Edition (2021) (E book) Useful chapter for considering in vitro and in vivo screens for your chosen target ? A Pharmacology Primer, Techniques for More Effective and Strategic Drug Discovery Terry Kenakin 4th Edition (April 2014) (E-book) Some good chapters on screening and safety pharmacology. ? Nature Reviews Drug Discovery journal http://www.nature.com/nrd/index.html ? Drug Discovery Today journal https://www.journals.elsevier.com/drug-discoverytoday/ ? Drug discovery journal http://discoveryjournals.org/drugdiscovery/index.htm ? Assay and development technologies https://home.liebertpub.com/publications/assay-and-drug-developmenttechnologies/118/ Table 1. Assigned Target Student Target Therapeutic area Alonge,Oluwatosin Bukola HMGB1 cancer Anil Kumar,Aswathy IDO1 cancer Bellenie,Rhea TIGIT cancer Davis,Liam LAG3 cancer Makore,Martin SHP2 cancer Saqi,Shahryar PD-1 cancer Dutta,Zinia CTLA-4 cancer Grealy,Fiona HLA-G cancer Abdullah,Hamzah P2Y2 neurodegenerative disease Abimbola,Bolaji Temitope EP1 (prostanoid) neurodegenerative disease Abu Laban Zarour,Amira STEP (STriatal Enriched Phosphatase) neurodegenerative disease Ahmad,Ausaf 5-HT6 neurodegenerative disease Anthony,Mercy H3 (histamine) anxiety related disorder or neurodegenerative disease Borkhataria,Kennery OX1 (orexin receptor 1) anxiety related disorder Bugalho Morgado,Catarina Isabel V1A (vasopressin) anxiety related disorder Dalia Mercy Aloysius,Z GAL2 (Galanin 2) anxiety related disorder Farheen,Samina NK3 (Tachykinin) anxiety related disorder Fatima,Batool TRPM2 pain / inflammation George,Jeeva TRPM3 pain / inflammation George,Shona Therampalliyil TRPC5 pain / inflammation Haque,Samia TRPV4 pain / inflammation Karuppaiya,Mathan cGRP pain / inflammation Khan,Ayesha Shoeb PAR4 (Proteinase-activated) pain / inflammation Kunjunju Joseph,Jomon EP1 (prostanoid) pain / inflammation Owusu Ansah,Dinah PAR2 (Proteinase-activated) pain / inflammation Pan,Ywal Hmue H3 (histamine) pain / inflammation Filova, Jana GAL1 receptor (galanin) pain / inflammation Peravali,Sravan Kumar SSAO cardiovascular disease Samuel,Covenant Akinjesu VGEF cardiovascular disease Shaw,Emily CD28 cardiovascular / respiratory/ immune Sheeraz,Bilal Ahmad TASK-1 Inhibition cardiovascular (AF atrial fibrillation) Thomas,Elizabeth Galectin 3 (Gal-3) cardiovascular disease Ubale,Toshi PDE5 cardiovascular disease Vanjeeswaran,Gopiga IL17 respiratory (asthma) Gulzar,Aneysah CXCR4 respiratory (asthma) Aryoobi,Rustam LTbR respiratory (COPD) Stoute,Chenayi 5-LOX respiratory (asthma)

Attachments:

7lms0271-tms-....pdf